Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 1 Demographic and clinical characteristics of nAMD patients and controls

From: Higher plasma levels of complement C3a, C4a and C5a increase the risk of subretinal fibrosis in neovascular age-related macular degeneration

 

All

Controls

nAMD

P value

(n = 139)

(n = 43)

(n = 96)

nAMD vs Control

Age (median (range)), years

78.6 (53–93)

74.0 (58–92)

80.1 (53–93)

0.002 a

Female (number (%))

63 (45)

19 (44)

44 (46)

1.000b

Family history of AMD (number (%))

32 (23)

6 (14)

26 (27)

0.127b

History of cardiovascular disease (number (%))

36 (26)

9 (21)

27 (28)

0.528b

History of hypertension (number (%))

81 (58)

23 (53)

58 (60)

0.576b

History of diabetes (number (%))

15 (11)

2 (5)

13 (14)

0.150b

Body Mass Index (mean ± SD)

26.1 ± 4.4

26.1 ± 5.1

26.0 ± 4.0

0.980c

Smoking status

   

0.381b

 Non-smoker (number (%))

56 (40)

20 (47)

36 (38)

 

 Former smoker (number (%))

70 (50)

20 (47)

50 (52)

 

 Current smoker (number (%))

12 (9)

2 (5)

10 (10)

 

Taking cardiovascular medication (number (%))

102 (73)

28 (65)

74 (77)

0.212b

Taking vitamins (number (%))

28 (20)

3 (7)

25 (26)

0.011 b

Taking low-dose aspirin (number (%))

43 (31)

5 (12)

38 (40)

0.001 b

  1. aMann Whitney U test
  2. bPearson’s chi-square test
  3. cIndependent samples t-test
  4. SD standard deviation
  5. Bold P < 0.05